Trial Profile
A prospective, phase III trial to evaluate the efficacy and safety of HIV vaccine [Biosantech] in patients with HIV infections
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 18 Mar 2016
Price :
$35
*
At a glance
- Drugs HIV vaccine (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- 18 Mar 2016 New trial record
- 15 Mar 2016 According to Biosantech media release, based on the results of its IIa trial (see CTP700229617), the company will put forward request for this phase III trial of its anti-HIV vaccine for an extensive evaluation during 2016. Subject to approval by the regulatory authorities and the results of this trial, an initial anti-HIV vaccine would be available from the H2 of 2018. The company intends to request a MAA for its anti-HIV vaccine in second half of 2018.